WO2017094204A1 - Luliconazole as anti-acanthamoeba agent and method for producing the same - Google Patents

Luliconazole as anti-acanthamoeba agent and method for producing the same Download PDF

Info

Publication number
WO2017094204A1
WO2017094204A1 PCT/JP2016/003106 JP2016003106W WO2017094204A1 WO 2017094204 A1 WO2017094204 A1 WO 2017094204A1 JP 2016003106 W JP2016003106 W JP 2016003106W WO 2017094204 A1 WO2017094204 A1 WO 2017094204A1
Authority
WO
WIPO (PCT)
Prior art keywords
plane
luliconazole
crystal
acanthamoeba
diffraction peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2016/003106
Other languages
English (en)
French (fr)
Inventor
Yoshiyuki Miyata
Takaaki Masuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Priority to US15/781,030 priority Critical patent/US20200268716A1/en
Publication of WO2017094204A1 publication Critical patent/WO2017094204A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to anti-Acanthamoeba agents useful against infections caused by Acanthamoebae as pathogens, such as keratopathy and encephalitis.
  • Acanthamoebae which are amoeboid protozoans as well as basically ingest bacteria and freely live, occasionally cause infections such as keratitis and encephalitis. At present, there is no drug effective against such infections caused by Acanthamoebae. When being serious, such infections may cause blindness and may result in death due to opportunistic infections in rare cases. Lactoferrin, lactoferricin, and the like, which have been reported as anti-Acanthamoeba agents in patent literatures, have had difficulty in exerting effects in practical application (see, for example, Patent Literature 1). Acanthamoebae includes several known subspecies such as A. castellanii and A.
  • Luliconazole which has been already marketed as an antifungal agent, has been already known, e.g., to have action against Trichomonas, and to have several crystal habits, resulting in different extents of action against Trichomonas (see, for example, Patent Literatures 2 to 9). There is also a literature insisting that there is another crystal system with regard to luliconazole crystals (see, for example, Patent Literature 10).
  • luliconazole has not been known to have anti-Acanthamoeba activity at all, and the anti-Acanthamoeba activity has not been known to differ according to a crystal habit at all either.
  • a luliconazole crystal having a crystal habit in which (20-2) plane or (10-2) plane are specific growth planes has not been known at all either.
  • Patent Literature 1 Japanese Patent Laid-Open No. 2011-246458 Patent Literature 2: Japanese Patent Laid-Open No. 2015-91890 Patent Literature 3: Japanese Patent Laid-Open No. 2015-63566 Patent Literature 4: Japanese Patent Laid-Open No. 2015-51945 Patent Literature 5: Japanese Patent Laid-Open No. 2015-27984 Patent Literature 6: Japanese Patent Laid-Open No. 2015-27983 Patent Literature 7: Japanese Patent Laid-Open No. 2015-27972 Patent Literature 8: Japanese Patent Laid-Open No. 2014-172858 Patent Literature 9: Japanese Patent Laid-Open No. 2014-74008 Patent Literature 10: Chinese Patent No. 103012385
  • Non Patent Literature 1 J. Clin. Microbiol. 2012, 50(3), 1128-31
  • Non Patent Literature 2 BMJ Case Rep. 2009, pii: bcr08. 2008. 0642
  • Non Patent Literature 3 Environ. Microbiol. 2006, 8(6), 1130-3
  • the present invention was made under such circumstances with an object to provide a novel anti-Acanthamoeba agent.
  • the present inventors persevered in intensive research efforts for a novel anti-Acanthamoeba agent with respect to such circumstances, and found that luliconazole has anti-Acanthamoeba activity, and the invention was thus accomplished.
  • a crystal having a crystal habit in which (20-2) plane and/or (10-2) plane are specific growth planes is particularly excellent in such action, and the invention was further expanded.
  • the present invention is as described below.
  • An anti-Acanthamoeba agent comprising luliconazole as an active ingredient.
  • luliconazole as an active ingredient.
  • ⁇ 8> A method for producing the luliconazole crystal as defined in any one of ⁇ 5> to ⁇ 7>, the method comprising recrystallizing luliconazole with acetonitrile that may contain a polar solvent.
  • the polar solvent is selected from water, methanol, ethanol, ethyl acetate, acetone, dimethylsulfoxide, and dimethylformamide.
  • ⁇ 10> A method for producing the luliconazole crystal as defined in any one of ⁇ 5> to ⁇ 7>, the method comprising recrystallizing luliconazole with a mixed solvent of an aprotic polar solvent and a protic polar solvent.
  • ⁇ 11> The production method according to any one of ⁇ 8> to ⁇ 10>, wherein a solvent selected from normal hexane, cyclohexane, and petroleum ether is used as a poor solvent.
  • a novel anti-Acanthamoeba agent can be provided.
  • Fig. 1 is a view showing the measured X-ray powder diffraction data of crystal in Example 2.
  • Fig. 3 illustrates the microphotographs of crystals in Examples 2 to 6 (photographs substituted for the drawing).
  • Fig. 3(a) illustrates the crystal in Example 2
  • Fig. 3(b) illustrates the crystal in Example 3
  • Fig. 3(c) illustrates the crystal in Example 4
  • Fig. 3(d) illustrates the crystal in Example 5
  • Fig. 3(e) illustrates the crystal in Example 6.
  • An anti-Acanthamoeba agent of the present invention comprises luliconazole as an active ingredient.
  • Luliconazole having a structure described below, has been already marketed and used as an antifungal agent.
  • Such luliconazole can be synthesized according to a method described, for example, in Japanese Patent Laid-Open No. 60-218387.
  • a compound represented by the general formula (1) can be obtained by allowing 1-cyanomethylimidazole to react with carbon disulfide to obtain a compound (III), which is allowed to react with a compound of the general formula (II) having leaving groups. After the reaction, the compound may be purified by a recrystallization method as a usual method.
  • R and X represent a hydrogen atom or a halogen atom.
  • Preferred examples of such leaving groups Y and Y' include methanesulfonyloxy group, benzenesulfonyloxy group, p-toluenesulfonyloxy group, or a halogen atom (see the following scheme).
  • Luliconazole Crystal Luliconazole exhibits excellent anti-Acanthamoeba activity.
  • the anti-Acanthamoeba agent of the present invention can be applied, without particular limitation, to microorganisms that are classified into Acanthamoebae and are responsible for diseases such as keratitis.
  • the anti-Acanthamoeba agent of the present invention well inhibits the growth of the microorganisms.
  • luliconazole exhibits anti-Acanthamoeba activity even when being solid, i.e., a crystal in itself, and exhibits a similar effect even when being in a solution state.
  • Luliconazole is difficult to dissolve in an aqueous carrier, and a solvent such as ethanol, benzyl alcohol, N-alkylpyrrolidone, or diisopropyl adipate is required for locally administering homogeneously dissolved luliconazole to the affected area.
  • a solvent such as ethanol, benzyl alcohol, N-alkylpyrrolidone, or diisopropyl adipate is required for locally administering homogeneously dissolved luliconazole to the affected area.
  • a solvent such as ethanol, benzyl alcohol, N-alkylpyrrolidone, or diisopropyl adipate
  • the use of such a solvent is unfavorable because of resulting in the danger of damage to the cornea.
  • the administration of the anti-Acanthamoeba agent that is solid is preferable.
  • a dispersion liquid preparation in which a bulk powder is homogeneously dispersed in an aqueous medium that scarcely causes corneal disorders, or an ophthalmic ointment preparation in which such a bulk powder is homogeneously dispersed in an ointment base such as vaseline is preferred as a preparation for administration of such a solid against such a disease, i.e., a preparation in which luliconazole in solid (i.e., crystal) form is present in an agent (hereinafter also referred to as solid preparation).
  • a preparation for local administration in solid form it is preferable to use a crystal in which (20-2) plane and/or (10-2) plane are specific growth planes.
  • the specific growth plane of a crystal is a plane belonging to a peak of which the peak intensity is significantly great compared with the total sum of the peak intensities of the other diffraction peaks in the range of measured diffraction angles in the case of performing powder X-ray diffractometry.
  • the specific growth plane of a crystal can be detected, for example, as a peak of which the peak intensity of the diffraction peak is specifically high in the powder X-ray diffractometry of the crystal.
  • a value of 2 ⁇ in the vicinity of 24.4 ⁇ is, for example, in a range of 24.4 ⁇ ⁇ 0.7 ⁇ , preferably 24.4 ⁇ ⁇ 0.5 ⁇ .
  • a value of 2 ⁇ in the vicinity of 18.3 ⁇ is, for example, in a range of 18.3 ⁇ ⁇ 0.7 ⁇ , preferably 18.3 ⁇ ⁇ 0.5 ⁇ .
  • the value of I (10-2) / [I (001) + I (100) + I (10-1) + I (011) + I (110) + I (11-1) + I (10-2) + I (11-2) + I (020) + I (021) + I (20-2) + I (121) + I (013) + I (11-3) + I (221)] ⁇ 100 is preferably 20% or more, more preferably 25% or more, and still more preferably 30% or more. The upper limit of the value is presumed to be around 50% in view of practical maintenance of the properties of a crystal.
  • a particularly preferred embodiment is a crystal having both crystal habit properties in which (20-2) plane and (10-2) plane specifically grow.
  • the recrystallization which can be performed according to a usual method except for selection of the solvent, is preferably performed, for example, by dissolving the luliconazole crystals in the solvent under warming (ordinary at 40 to 80°C, preferably 40 to 60°C) to completely dissolve the crystal in the solvent, followed by cooling the resultant under stirring (ordinary at 5°C to room temperature), filtering the crystals, and drying the crystals by sending air at a low temperature of room temperature to around 40°C.
  • the recrystallization can also be performed by completely dissolving the crystals in the solvent, followed by evaporating the solvent.
  • Preferred examples of the polar solvent include water, methanol, ethanol, ethyl acetate, acetone, dimethylsulfoxide, and dimethylformamide, and a polar solvent selected from water, methanol, ethanol, ethyl acetate, dimethylsulfoxide, and dimethylformamide is more preferred.
  • the amount of the added polar solvent is ordinarily 5 to 95 mass%, preferably 7 to 75 mass%, and more preferably 7 to 20 mass% with respect to the mass of the acetonitrile.
  • a method for recrystallizing luliconazole crystals with the mixed solvent of an aprotic polar solvent and a protic polar solvent can also be used in the method for producing a crystal in which (20-2) plane and/or (10-2) plane are specific growth planes.
  • Preferred examples of the aprotic polar solvent include ethyl acetate, acetone, dimethylsulfoxide, and dimethylformamide.
  • Preferred examples of the protic polar solvent include water, methanol, and ethanol.
  • the mixture ratio (mass ratio) between the aprotic polar solvent and the protic polar solvent can be selected in consideration of the solubility of the crystals, the boiling point of the solvent, and the like, and is ordinarily 9: 1 to 1: 9, preferably 7: 3 to 3: 7, more preferably 3: 2 to 2: 3, and still more preferably 4: 3 to 3: 4.
  • the step of the recrystallization can be performed in a manner similar to the recrystallization using the acetonitrile.
  • a nonpolar solvent such as normal hexane, cyclohexane, or petroleum ether can also be added as a poor solvent.
  • the amount of the added poor solvent is ordinarily appropriately 5 to 60 mass%, preferably 7 to 50 mass%, and more preferably 10 to 40 mass% with respect to the total sum of the other solvents.
  • the preferred average particle diameter of the crystals used in the present invention is 10 to 500 ⁇ m, more preferably 50 to 400 ⁇ m, and still more preferably 150 to 300 ⁇ m. This is because the too small average particle diameter may unfavorably result in a small crystal habit while the too large average particle diameter may result in constitution of an obstacle to administration.
  • the crystals satisfying such an average particle diameter are obtained, for example, by such a method as described above.
  • the average particle diameter of luliconazole can be measured and obtained as a number average particle diameter.
  • the number average particle diameter can be measured and obtained as the average diameter of particles by analyzing a microscope image. For example, the measurement is performed in the following procedure.
  • a powder of luliconazole is observed using, as an inverted microscope, an inverted microscope Diaphot manufactured by NIKON CORPORATION. Then, optional particles are selected, and the particle diameters of the particles are measured. In such a case, the measurement is performed for 100 or more particles. Further, the average particle diameter of luliconazole can be obtained as an average particle diameter measured and obtained with a laser diffraction-type particle size distribution measuring apparatus.
  • Luliconazole crystals obtained by, for example, recrystallization and/or the like may be ground in a wet or dry process by a usual method in order to adjust the average particle diameter of the crystals, and preferred examples of instruments used in the grinding include jet mills, dinomills, cobol mills, mortar machines, and ball mills.
  • instruments used in the grinding include jet mills, dinomills, cobol mills, mortar machines, and ball mills.
  • an excipient such as starch or cellulose, a lubricant such as magnesium stearate, and/or the like, and to perform the treatment.
  • a medium mill such as a dinomill or a cobol mill
  • a ball mill may be used in wet or dry grinding.
  • the anti-Acanthamoeba agent of the present invention may have an embodiment in which the agent consists of luliconazole, or may have an embodiment in which the agent further contains, e.g., an optional ingredient that is ordinarily used for preparation unless interfering with the effects of the present invention.
  • One preferred embodiment of the anti-Acanthamoeba agent of the present invention is a preparation in which solid luliconazole is present in the agent (solid preparation).
  • the solid preparation examples include: solid preparations such as tablets, capsules, and powders; semisolid preparations such as ointments and creams; and solid dispersion liquid preparations in which a solid is dispersed in an aqueous medium.
  • an orally-administered agent such as a tablet or a capsule
  • an external preparation such as an ointment, a cream, or a solid dispersion liquid preparation, together with an optional ingredient such as an excipient, a disintegrant, a binder, a flavoring agent, a dispersant, an emulsifier, or an aqueous medium
  • a powder together with an optional ingredient such as an extender; or the like.
  • Particularly preferred examples include a directly intraocularly administered powder, an aqueous medium dispersion preparation, or an ophthalmic ointment in ointment form.
  • the anti-Acanthamoeba agent of the present invention is processed into an anti-Acanthamoeba composition such as a medicine
  • the content of luliconazole which is an active ingredient is ordinarily 0.1 to 50 mass% and preferably 0.5 to 15 mass% with respect to the total amount of the composition.
  • the anti-Acanthamoeba agent of the present invention can be used for preventive and therapeutic applications against infections caused by Acanthamoeba, for example, keratitis.
  • the dosage form of the anti-Acanthamoeba agent of the present invention can be selected as appropriate in consideration of the body weight, age, sex, symptom, and/or the like of a patient, and in the case of an adult, it is preferable to administer the preparation with the active ingredient in an amount of ordinarily 1 to 100 mg daily. It is preferable to perform the administration once daily or twice daily.
  • Acanthamoeba polyphaga (A. polyphaga; clinical isolate) was cultured in an ATCC712 medium (hereinafter simply referred to as medium) at 25°C for 1 week, and the medium was adjusted by adding a medium so that the number of the amoebae was 100,000 amoebae/mL, to make a preculture liquid.
  • a control and samples were prepared by adding 4.3 mL of medium, 200 ⁇ L of specimen, and 500 ⁇ L of preculture liquid. The amoebae were cultured at 25°C for 72 hours, and the number of the amoebae was counted by a Neubauer counting chamber. Luliconazole used in the specimen was obtained as described below.
  • a compound was synthesized according to a method described in Japanese Patent Laid-Open No. 60-218387, an ethyl acetate/normal hexane mixture (5: 1) was added, and the resultant was warmed at 60°C and dissolved under stirring. Crystals were precipitated while stirring the resultant in cooling water at 5°C, were filtered, and dried by sending air at 40°C for 48 hours to obtain the crystals.
  • the specimen was prepared using methanol as a solvent so that the final concentration of luliconazole was 0, 5, 10, 20, or 40 ⁇ g/mL. The specimen in which the final concentration of luliconazole was 0 ⁇ g/mL was used as the control.
  • Growth inhibition rates were determined based on [(the number of amoebae in control - the number of amoebae in each sample) / the number of amoebae in control] ⁇ 100.
  • MIC and IC 50 were calculated based on the growth inhibition rates by a usual method. The growth inhibition rates were listed in Table 1. MIC was 40 ⁇ g/mL, and IC 50 was 20 ⁇ g/mL.
  • Example 2 In order to produce a solid preparation, crystals having a crystal habit were produced on the following conditions. (Solvent) Acetonitrile (Crystallization Method) Evaporation method (Luliconazole was dissolved at 50°C, and cooled to room temperature. Then, when residual crystals were present, the crystals were removed.
  • the solvent was evaporated at room temperature for 1 day to result in recrystallization, and filtration and air drying were performed.
  • the powder X-ray diffractometry (apparatus model name: XRD-DSCII; manufacturer name: Rigaku Corporation; conditions: X-ray source: CuK ⁇ ; measurement temperature: room temperature; tube voltage: 40 kV; tube current: 40 mA; 2 ⁇ : 5 to 35 ⁇ ; step angle: 0.05 ⁇ ) of the obtained crystals revealed that a diffraction pattern as listed in Table 2 below was shown. Further, the results of the powder X-ray diffractometry are shown in Figure 1. It is revealed that the crystals were the luliconazole crystals of the present invention.
  • a crystal plane corresponding to each diffraction peak was identified by comparison with data from single-crystal X-ray structure analysis (apparatus model name: RU-H2R; manufacturer name: Rigaku Corporation; conditions: X-ray source: CuK ⁇ ; measurement temperature: 26°C; tube voltage: 50 kV; tube current: 180 mA; 2 ⁇ max: 150.0 ⁇ ; structure analysis method: direct method (SHELX86)).
  • the various data obtained from the single-crystal X-ray structure analysis are shown below and in Figure 2. Specifically growing crystal planes were specified from the ratios of diffraction peak intensities by comparing the data with the powder X-ray diffractometry data. The results are listed in Table 2.
  • Each peak intensity ratio is a ratio with respect to the total sum of the peak intensities of diffraction peaks corresponding to (001) plane, (100) plane, (10-1) plane, (011) plane, (110) plane, (11-1) plane, (10-2) plane, (11-2) plane, (020) plane, (021) plane, (20-2) plane, (121) plane, (013) plane, (11-3) plane, and (221) plane.
  • Example 3 Dissolution was performed with an ethyl acetate/normal hexane mixture (4: 3) as a recrystallization solvent under reflux for 2 hours, the residue was removed by filtration, ice cooling under stirring was carried out to perform recrystallization, and filtration and air drying were performed for 4 hours to obtain crystals which are the anti-Acanthamoeba agent of the present invention.
  • Powder X-ray analysis was performed in like manner with Example 2. The X-ray powder diffraction data of the resultant is as described below.
  • Example 4 Dissolution was performed with a methanol/dimethylsulfoxide mixture (1: 1) as a recrystallization solvent at 50°C. Then, when residual crystals were present, the crystals were removed. Cooling at 5°C was carried out to perform recrystallization, and filtration and air drying were performed to obtain crystals which were the anti-Acanthamoeba agent of the present invention. Powder X-ray analysis was performed in like manner with Example 2. The X-ray powder diffraction data of the resultant is as described below.
  • Example 5 Dissolution was performed with acetonitrile as a recrystallization solvent at 50°C. Then, when residual crystals were present, the crystals were removed. Cooling at room temperature was carried out to perform recrystallization, and filtration and air drying were performed to obtain crystals which were the anti-Acanthamoeba agent of the present invention. Powder X-ray analysis was performed in like manner with Example 2. The X-ray powder diffraction data of the resultant is as described below.
  • Example 6 Dissolution was performed with methanol as a recrystallization solvent at 50°C, and cooling to 25°C was carried out. Then, when residual crystals were present, the crystals were removed. Then, normal hexane was added as a poor solvent, recrystallization was performed at 25°C under stirring, and filtration and air drying were performed to obtain crystals which were the anti-Acanthamoeba agent of the present invention. Powder X-ray analysis was performed in like manner with Example 2. The X-ray powder diffraction data of the resultant is as described below.
  • Example 7 The anti-Acanthamoeba activities of the crystals in Examples 2 to 6 were examined based on the method in Example 1.
  • Acanthamoeba polyphaga (A. polyphaga) of which the number of the amoebae was 50,000 with respect to 4.5 mL of ATCC712 medium was dispersed and seeded in 500 ⁇ L of medium, and was preliminarily cultured at 25°C for 48 hours.
  • 1 mg of each of the crystals in Examples 2 to 6 was added to prepare a control and samples. The culture was further continued at 25°C for 72 hours, and the number of the amoebae in the culture liquid was measured by a Neubauer counting chamber.
  • the control to which nothing was added, and in which the amoebae were cultured, was used. Growth inhibition rates were calculated from the counted values according to an expression of [(the number of amoebae in control - the number of amoebae in each sample) / the number of amoebae in control] ⁇ 100.
  • This results are listed in Table 7.
  • the average particle diameters of the crystals in Examples 2 to 6 were measured using an inverted microscope. In other words, three samples in each of the crystals of the examples were sampled. Using an inverted microscope Diaphot (40 times) manufactured by NIKON CORPORATION, the particle diameters of each sample were actually measured in 10 visual fields with a slide glass measure, and the average particle diameter thereof was measured. The particle diameters of the three samples were further averaged to obtain an average particle diameter. The results are listed in Table 7. The microphotographs of the crystals in Examples 2 to 6 are shown in Figure 3.
  • the peak intensity ratio of (20-2) plane is preferably 12% or more, more preferably 15% or more, and still more preferably 19% or more for crystals used in the anti-Acanthamoeba agent of the present invention. Further, it is found that the peak intensity ratio of (10-2) plane is preferably 20% or more, more preferably 25% or more, and still more preferably 30% or more. Further, it is found that it is preferable to satisfy both of such conditions.
  • Ophthalmic ointments were produced using the anti-Acanthamoeba agent of the present invention according to the following prescription.
  • formulation ingredients were kneaded by a kneader under sterile conditions to obtain the ophthalmic ointments (unit: part(s) by mass).
  • Ophthalmic powders were produced using the anti-Acanthamoeba agent of the present invention according to the following prescription.
  • formulation ingredients were kneaded by a kneader under sterile conditions to obtain the ophthalmic powders (unit: part(s) by mass).
  • compositions in aqueous medium dispersant form were produced using the anti-Acanthamoeba agent of the present invention according to the following prescription.
  • formulation ingredients were stirred to make homogeneous dispersion preparations, which were dispensed, sealed, and then sterilized in an autoclave (120°C, 15 minutes) to obtain the aqueous external preparations of the present invention (unit: percent(s) by mass).
  • the present invention can be applied to a medicine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/JP2016/003106 2015-12-04 2016-06-28 Luliconazole as anti-acanthamoeba agent and method for producing the same Ceased WO2017094204A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/781,030 US20200268716A1 (en) 2015-12-04 2016-06-28 Luliconazole as anti-acanthamoeba agent and method for producing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015237951A JP2017101009A (ja) 2015-12-04 2015-12-04 抗アカントアメーバ剤及びその製造法
JP2015-237951 2015-12-04

Publications (1)

Publication Number Publication Date
WO2017094204A1 true WO2017094204A1 (en) 2017-06-08

Family

ID=56413827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/003106 Ceased WO2017094204A1 (en) 2015-12-04 2016-06-28 Luliconazole as anti-acanthamoeba agent and method for producing the same

Country Status (5)

Country Link
US (1) US20200268716A1 (https=)
JP (1) JP2017101009A (https=)
KR (1) KR20170066196A (https=)
CN (1) CN106822104A (https=)
WO (1) WO2017094204A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019150383A1 (en) * 2018-02-05 2019-08-08 Nalla Surya Prakash Rao A process for preparation of luliconazole
EP3866792A4 (en) * 2018-10-17 2022-10-19 Georgia State University Research Foundation, Inc. TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60218387A (ja) 1984-04-14 1985-11-01 Nippon Nohyaku Co Ltd ケテンｓ，ｓ−アセタ−ル類
JP2011246458A (ja) 2010-04-28 2011-12-08 Tamagawa Gakuen 抗アカントアメーバ用組成物、アカントアメーバ角膜炎の予防及び治療剤並びにコンタクトレンズケア溶液
CN103012385A (zh) 2012-02-17 2013-04-03 山东威智医药工业有限公司 卢立康唑的晶型及其制备方法
WO2014041708A1 (en) * 2012-09-14 2014-03-20 Pola Pharma Inc. Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
JP2014172858A (ja) 2013-03-08 2014-09-22 Pola Pharma Inc 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP2015027984A (ja) 2013-06-24 2015-02-12 株式会社ポーラファルマ 結晶及び該結晶を含有してなる医薬製剤
JP2015027972A (ja) 2012-09-14 2015-02-12 株式会社ポーラファルマ 結晶及び該結晶を含有してなる医薬製剤
WO2015033612A1 (en) * 2013-09-06 2015-03-12 Pola Pharma Inc. Crystal having specific crystal habit and pharmaceutical composition containing the crystal as active ingredient
JP2015063566A (ja) 2015-01-06 2015-04-09 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
WO2016092478A1 (en) * 2014-12-12 2016-06-16 Glenmark Pharmaceuticals Limited Process for preparation of luliconazole

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60218387A (ja) 1984-04-14 1985-11-01 Nippon Nohyaku Co Ltd ケテンｓ，ｓ−アセタ−ル類
JP2011246458A (ja) 2010-04-28 2011-12-08 Tamagawa Gakuen 抗アカントアメーバ用組成物、アカントアメーバ角膜炎の予防及び治療剤並びにコンタクトレンズケア溶液
CN103012385A (zh) 2012-02-17 2013-04-03 山东威智医药工业有限公司 卢立康唑的晶型及其制备方法
JP2015027972A (ja) 2012-09-14 2015-02-12 株式会社ポーラファルマ 結晶及び該結晶を含有してなる医薬製剤
WO2014041708A1 (en) * 2012-09-14 2014-03-20 Pola Pharma Inc. Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
JP2014074008A (ja) 2012-09-14 2014-04-24 Pola Pharma Inc 晶癖を有する結晶及び該結晶を加工してなる医薬組成物
JP2014172858A (ja) 2013-03-08 2014-09-22 Pola Pharma Inc 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP2015027984A (ja) 2013-06-24 2015-02-12 株式会社ポーラファルマ 結晶及び該結晶を含有してなる医薬製剤
JP2015027983A (ja) 2013-06-24 2015-02-12 株式会社ポーラファルマ 結晶及び該結晶を含有してなる医薬製剤
JP2015091890A (ja) 2013-06-24 2015-05-14 株式会社ポーラファルマ 結晶及び該結晶を含有してなる医薬製剤
WO2015033612A1 (en) * 2013-09-06 2015-03-12 Pola Pharma Inc. Crystal having specific crystal habit and pharmaceutical composition containing the crystal as active ingredient
JP2015051945A (ja) 2013-09-06 2015-03-19 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
WO2016092478A1 (en) * 2014-12-12 2016-06-16 Glenmark Pharmaceuticals Limited Process for preparation of luliconazole
JP2015063566A (ja) 2015-01-06 2015-04-09 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BMJ CASE REP., 2009
DART J K G ET AL: "Acanthamoeba Keratitis: Diagnosis and Treatment Update 2009", AMERICAN JOURNAL OF OPHTHALMOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 148, no. 4, 1 October 2009 (2009-10-01), pages 487 - 499.e2, XP026700496, ISSN: 0002-9394, [retrieved on 20090805], DOI: 10.1016/J.AJO.2009.06.009 *
ENVIRON. MICROBIOL., vol. 8, no. 6, 2006, pages 1130 - 3
J. CLIN. MICROBIOL., vol. 50, no. 3, 2012, pages 1128 - 31

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019150383A1 (en) * 2018-02-05 2019-08-08 Nalla Surya Prakash Rao A process for preparation of luliconazole
EP3866792A4 (en) * 2018-10-17 2022-10-19 Georgia State University Research Foundation, Inc. TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS
US12433872B2 (en) 2018-10-17 2025-10-07 Georgia State University Research Foundation, Inc. Treatment of Acanthamoeba or Balamuthia trophozoites and/or cysts

Also Published As

Publication number Publication date
JP2017101009A (ja) 2017-06-08
US20200268716A1 (en) 2020-08-27
KR20170066196A (ko) 2017-06-14
CN106822104A (zh) 2017-06-13

Similar Documents

Publication Publication Date Title
US20230167069A1 (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
KR101751726B1 (ko) 특이한 정벽을 가지는 결정형 및 이 결정형을 유효 성분으로서 함유하는 약학 조성물
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
EP4010322B1 (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
JP7537811B2 (ja) カリプラジン医薬組成物、製造方法及び応用
CN107056813B (zh) 德罗格韦钠盐的晶型及其制备方法
US20230049311A1 (en) Methods of treating desmoid tumors with (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide
JP2016511273A (ja) Ｄ−グルシトール，１−デオキシ−１−（メチルアミノ）−，１−（６−アミノ−３，５−ジフルオロピリジン−２−イル）−８−クロロ−６−フルオロ−１，４−ジヒドロ−７−（３−ヒドロキシアゼチジン−１−イル）−４−オキソ−３−キノリンカルボン酸塩の結晶型
WO2017094204A1 (en) Luliconazole as anti-acanthamoeba agent and method for producing the same
US20240116853A1 (en) 2-hydroxy-5-[2-(4-(trifluoromethylphenyl)ethylamino)]benzoic acid crystal forms and preparation method therefor
JP7849971B2 (ja) テトラメチルピラジンニトロンの結晶形、製造方法及び使用
JP4516962B2 (ja) カルボスチリル誘導体アミン塩
AU2018256993A1 (en) Crystal form and salt of 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole
KR20050059132A (ko) 신규 결정
US11884634B2 (en) Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
WO2024062389A1 (en) Crystalline polymorph forms of a trpv1 antagonist and formulations thereof
KR20160098338A (ko) 코르티솔 17-알파-벤조에이트의 다형성 및 비결정성 형태들, 및 그 조제 방법들 및 용도
HK40074778A (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16739279

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16739279

Country of ref document: EP

Kind code of ref document: A1